Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Anika Therapeutics Inc. ANIK

Healthcare — Drug Manufacturers Specialty & Generic
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.26
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — 1 1 — — 1 —
Sell — — — — — — — — — — — —
Insider Ownership
5.93%

Capital & Financial Ratios

Market Cap
278.50
Revenue
120.65
Net Income
(3.78)
Free Cash Flow
0.56
Net Debt
(38.41)
Current Ratio
4.48
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
2.30
P/B ratio
2.02
Past 5Y EPS Growth
—
This Y EPS Growth
854.55%
Next Y EPS Growth
(9.52%)
Next 5Y EPS Growth
118.66%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 68.74 55.63 57.48 38.41
Receivables 26.36 23.59 23.69 29.06
Inventory 24.43 23.81 18.79 28.57
Other 36.31 5.13 — —
163.31 113.65 103.36 99.19
2023 2024 2025 Q'26
Payables 6.19 5.62 6.04 6.24
ST’ Debt — — — —
Other 10.80 4.12 — —
31.06 23.31 21.91 22.15
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 29.61 32.61 — —
—
’25 26.17 28.22 27.82 30.62
112.82
’24 29.02 30.72 29.56 30.60
119.91
’23 37.92 44.30 41.47 (2.90)
120.79
’22 36.69 39.66 40.26 (2.79)
113.83
’21 34.29 38.15 39.54 35.82
147.79
’20 35.40 30.68 31.69 32.69
130.46
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (4.85) (0.68) — —
—
’25 (0.13) (0.19) 6.87 4.64
11.19
’24 (0.13) (1.07) 5.02 1.58
5.40
’23 (3.62) (8.29) 6.49 3.64
(1.79)
’22 (1.87) 3.09 2.71 0.48
4.41
’21 (2.43) 4.29 2.06 4.47
8.40
’20 1.05 3.57 5.87 2.59
13.07
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (6.28) (2.13) — —
—
’25 1.54 (5.55) 4.98 3.99
4.96
’24 (1.93) (4.47) 3.20 0.28
(2.33)
’23 (5.01) (9.75) 5.74 1.80
(7.21)
’22 (3.19) 1.15 1.02 (2.05)
(3.08)
’21 (2.85) 1.98 0.78 3.35
3.25
’20 0.32 3.38 5.59 2.14
11.44
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.37) 0.24 — —
—
’25 (0.34) (0.28) (0.16) 0.02
(0.76)
’24 (0.31) (0.01) (2.03) (1.50)
(3.83)
’23 (0.71) (0.19) (0.45) (4.30)
(5.64)
’22 (0.20) (0.20) (0.29) (0.34)
(1.02)
’21 0.20 0.45 0.04 (0.40)
0.28
’20 0.24 (0.54) (0.45) (1.10)
(1.69)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 19.95 16.54 15.83 7.87 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 36.85 32.33 29.12 18.37 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 345 357 288 235 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.33 0.34 0.42 0.48 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 113.83 120.79 119.91 112.82 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 64.33% 68.33% 63.38% 56.56% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.32 3.16 (2.76) (9.31) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.80% 2.61% (2.31%) (8.25%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (14.86) (82.67) (56.38) (10.88) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.49 76.41 10.58 5.73 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.82 8.24 8.15 7.87 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ (1.02) (5.64) (3.83) (0.76) ‡‡‡‡‡ ‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.30 (0.12) 0.37 0.78 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.51) (0.37) (0.53) (0.43) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.21) (0.49) (0.16) 0.35 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.61 14.48 10.46 10.01 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.56 14.66 14.72 14.34 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.77 2.75 2.02 1.22 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.50 1.56 1.57 0.96 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.28 2.42 1.80 0.97 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (121.49) (40.56) (92.66) 22.09 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.41 (1.79) 5.40 11.19 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (7.49) (5.43) (7.73) (6.23) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.08) (7.21) (2.33) 4.96 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 141.63 132.25 90.35 81.45 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 30.89 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (55.44) (68.74) (55.63) (57.48) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 285.56 212.27 153.99 143.47 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.27%) (26.68%) (23.82%) (5.54%) ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.00% 0.37% (3.24%) (8.03%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.19%) (33.21%) (30.79%) (7.32%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Anika Therapeutics Inc. (ANIK), a specialist in hyaluronic acid-based orthobiologics for osteoarthritis, regenerative medicine, and sports injuries, showcases resilience amid medtech headwinds. After peaking at $148 million in revenue in 2021, sales stabilized around $120 million by 2024, with gross margins rebounding to 63.4% (nearing 68%) despite COVID disruptions and a $80 million goodwill impairment that drove net losses to $56 million. Fundamentals signal a turnaround, bolstered by a cash-rich balance sheet (net cash over $55 million), deleveraged position, and emerging positive free cash flow of $0.37 per share.

Analyst forecasts predict a modest 2025 revenue dip to $111 million before rebounding to $122 million by 2027, with EBT swinging to $6 million in 2025 and EPS narrowing losses 67% cumulatively. Trading at an EV/Sales of 1.8x—well below medtech peers at 4-6x—the stock implies 57% upside to consensus targets, fueled by operational streamlining (revenue per employee up to $416,000) and insider stability with no recent transactions.

Macro tailwinds from an aging population and 7% ortho market CAGR amplify ANIK’s disruptive edge in non-opioid injectables like Monovisc and CINGAL, positioning it for a profitability inflection and multi-year re-rating despite competition risks. With cleaner books and proven moats in cross-linked HA technology, ANIK offers compelling value for growth investors eyeing the rebound.

Read full commentary →

Anika Therapeutics Inc. (ANIK) Latest News

News by impact score

Fine-tune

21 Aug

3 , 11:39 AM
Anika Therapeutics Inc. stock rose 43.4% over the past three months. Three-month stock gains reflect positive developments with moderate influence on future performance.

7 Aug

3 transcript www.fool.com, 9:00 PM
Anika Therapeutics Inc. (ANIK) released the transcript of its Q2 2026 earnings call covering financial results and business updates. Quarterly earnings details can shift near-term stock sentiment and valuations but rarely alter long-term company trajectory.

3 , 8:55 AM
Anika Therapeutics Inc. (ANIK) stock shows upward movement with indications that the positive trend may persist due to underlying factors. Sustainable upward trend in ANIK stock may moderately influence investor sentiment and company valuation.

2 Aug

4 , 6:07 AM
Anika Therapeutics beat Q2 expectations and raised guidance, causing its stock fair value to rise. Q2 beat and higher guidance directly improve financial outlook and drive stock valuation higher.

29 Jul

4 , 5:02 PM
Anika Therapeutics reported record revenue and margins in Q2 2026 earnings call. Record Q2 2026 revenue and margins indicate strong performance likely to lift investor sentiment and company trajectory.

3 transcript app.moby.co, 3:16 PM
Anika Therapeutics Inc. issued a summary of its Q2 2026 earnings call covering financial results and outlook. Quarterly earnings data and guidance can shift near-term investor views on operations and valuation.

3 www.marketbeat.com, 10:04 AM
Anika Therapeutics reported Q2 results in its earnings call, covering revenue figures, operational updates, product pipeline progress and guidance for the remainder of the year. Quarterly earnings updates supply fresh financial data that can shift near-term valuation and sentiment without altering long-term strategy.

3 , 7:05 AM
Anika Therapeutics Inc. released second quarter 2026 financial results. Quarterly earnings data can shift near-term valuation and sentiment without altering long-term strategy.

3 May

4 Simply Wall St., 9:36 AM
Anika Therapeutics Inc. (ANIK) President acquires 51% more company stock, signaling strong insider confidence. President's 51% stock increase demonstrates significant insider optimism, potentially driving positive market sentiment and stock performance.

29 Apr

3 app.moby.co, 12:50 PM
Anika Therapeutics, Inc. (ANIK) Q1 2026 earnings call summary highlights quarterly financial results, operational updates, strategic initiatives, and forward guidance. Quarterly earnings summaries impact financial performance and investor sentiment moderately.

3 www.marketbeat.com, 10:20 AM
Anika Therapeutics Inc. (ANIK) released Q1 earnings call highlights detailing financial results, revenue growth, product performance, and future guidance amid orthopedic and regenerative medicine segments. Q1 earnings highlights cover financial metrics and strategic updates with moderate influence on investor sentiment and short-term stock performance.

3 GlobeNewswire, 7:05 AM
Anika Therapeutics Inc. (ANIK) reported first quarter 2026 financial results, highlighting key revenue, net income, and operational updates. Quarterly earnings reports typically affect financial performance and investor sentiment but are balanced by ongoing operations.

3 Mar

4 www.marketbeat.com, 3:29 AM
Anika Therapeutics (ANIK) highlighted a $3 billion total addressable market and detailed growth plans for Cingal and Hyalofast products at the Canaccord MSK Conference. Touted $3B TAM and specific product growth plans signal major strategic positioning likely to boost investor sentiment and alter market trajectory.

27 Feb

4 app.moby.co, 8:30 AM
Anika Therapeutics, Inc. (ANIK) Q4 2025 earnings call summary covers financial results, operational highlights, and forward guidance for the orthopedic and regenerative medicine company. Q4 2025 earnings results, guidance, and strategic updates directly shape ANIK's financial trajectory and investor sentiment.

26 Feb

4 GuruFocus.com, 4:09 PM
Anika Therapeutics Inc (ANIK) Q4 2025 earnings call highlights strong international growth and other key developments. Strong international growth reported in Q4 2025 earnings significantly boosts ANIK's market performance and future prospects.

4 www.marketbeat.com, 10:59 AM
Anika Therapeutics Inc. (ANIK) Q4 earnings call highlighted financial results, operational updates, and forward guidance for the orthobiologics company. Q4 earnings call highlights reveal key financial performance and strategic outlook directly impacting stock price and investor confidence.

4 Associated Press Finance, 7:35 AM
Anika Therapeutics Inc. (ANIK) released Q4 earnings snapshot. Q4 earnings snapshots reveal financial performance that significantly impacts stock price and investor sentiment.

4 , 7:05 AM
Anika Therapeutics Inc. (ANIK) reported fourth quarter and full year 2025 financial results, highlighting key revenue, net income, and operational metrics. Earnings reports reveal financial health and guide future performance expectations, significantly swaying investor sentiment and stock trajectory.

3 Zacks, 12:15 PM
Anika Therapeutics Inc. (ANIK) reported Q4 earnings and revenues that beat analyst estimates. Beating Q4 earnings and revenue estimates positively influences financial performance and investor sentiment with moderate long-term effects.

4 Feb

3 , 8:54 AM
Lumicell has appointed Cheryl R. Blanchard, Ph.D., a seasoned leader in biotech and medtech, to its Board of Directors. Blanchard brings extensive experience, having held leadership roles at various companies, including her previous position as CEO of Anika Therapeutics. Her expertise is expected to enhance Lumicell's strategic direction and innovation in the medical technology sector. The appointment of a seasoned leader may positively influence Lumicell's strategic direction and innovation, impacting its competitive positioning.

8 Jan

3 GlobeNewswire, 7:00 AM
Anika Therapeutics Inc. announced a leadership transition, with the appointment of a new CEO to drive the company's strategic vision and growth. The change aims to enhance operational efficiency and strengthen the company's position in the market. The outgoing CEO will assist in the transition process to ensure continuity in leadership and strategy execution. Leadership transitions can moderately influence company performance and strategic direction.

3 Dec

3 Simply Wall St., 5:15 AM
Anika Therapeutics, Inc. (NASDAQ:ANIK) is reportedly undervalued by 39%, according to analysts who believe the company's stock price does not reflect its potential growth and market position. The firm has been focusing on expanding its product offerings and improving its financial performance, which may lead to a reassessment of its valuation by investors. Market dynamics and recent developments in the biotechnology sector could further influence investor sentiment towards Anika. The company's potential growth and market position may moderately influence its financial performance and investor sentiment.

6 Nov

4 transcript GuruFocus.comGuruFocus.comStockStoryAssociated Press FinanceSimply Wall St.GuruFocus.comGuruFocus.comZacks, 6:00 PM
Anika Therapeutics Inc. reported strong growth in its regenerative medicine segment during the Q3 2025 earnings call. The company highlighted increased revenues driven by innovative product launches and expanding market presence. Management expressed optimism about future growth prospects, citing ongoing investments in research and development. The positive financial results reflect the company's strategic focus on enhancing its product portfolio and addressing unmet medical needs in the orthopedic market. Strong growth in regenerative medicine and innovative product launches are likely to significantly impact future performance and investor sentiment.

5 Nov

4 transcript www.fool.com, 9:17 AM
Anika Therapeutics Inc. reported its Q3 2025 earnings, highlighting significant advancements in product development and financial performance. The company emphasized its commitment to innovation in regenerative medicine, showcasing new therapies and their potential market impact. Management provided insights into strategic initiatives aimed at enhancing shareholder value and expanding market reach. Overall, the earnings call reflected a positive outlook for the company's future growth and operational efficiency. Significant advancements in product development and strategic initiatives are likely to alter the company's trajectory and investor sentiment.

4 Zacks, 8:25 AM
Anika Therapeutics Inc. reported Q3 earnings and revenues that exceeded analysts' expectations, showcasing strong financial performance. The company highlighted growth in its product lines and positive market response, which contributed to the better-than-anticipated results. This performance reflects Anika's strategic initiatives and operational efficiencies, positioning it favorably in the competitive landscape. Earnings and revenue exceeding estimates indicate significant operational success and potential for future growth.

4 GlobeNewswire, 7:05 AM
Anika Therapeutics Inc. reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue growth and product performance. The company experienced an increase in sales driven by its innovative therapies, particularly in the orthopedic sector. Management provided insights into future strategies and market positioning, emphasizing ongoing research and development efforts. The financial outlook remains positive, with expectations for continued growth in the upcoming quarters. Significant revenue growth and strategic initiatives are likely to impact future performance and investor sentiment.

4 , 7:00 AM
Anika Therapeutics Inc. has filed the final PMA module for its Hyalofast® cartilage repair scaffold, a significant step in the regulatory process. The company also released data from its U.S. pivotal FastTRACK Phase III study, which supports the product's efficacy and safety. This development is crucial for advancing the product towards market approval and addressing unmet needs in cartilage repair. The filing of the final PMA module and positive study data are likely to significantly impact Anika's future performance and market position.

3 , 8:13 PM
Anika Therapeutics Inc. (ANIK) is currently trading below its fair value, indicating a valuation discount that aligns with cautious market narratives. This situation raises concerns about investor sentiment and the company's future performance in a competitive landscape. The valuation discount suggests a moderately noticeable influence on market sentiment and potential financial performance.

3 Associated Press Finance, 7:22 AM
Anika Therapeutics Inc. reported its Q3 earnings, highlighting a decline in revenue compared to the previous year. The company faced challenges in its product sales, particularly in the orthopedic segment. Despite these setbacks, Anika is focusing on strategic initiatives to enhance its market position and drive future growth. The management expressed optimism about upcoming product launches and ongoing research efforts aimed at expanding its portfolio. Revenue decline and product sales challenges indicate a moderately noticeable influence on financial performance and market sentiment.

28 Oct

4 Simply Wall St., 12:22 PM
Anika Therapeutics Inc. (NASDAQ:ANIK) has garnered significant interest from institutional investors, with 60% of its shares owned by these entities. This strong institutional backing may indicate confidence in the company's future prospects and stability in the market. High institutional ownership typically reflects investor confidence and can influence stock performance positively.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us